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ABSTRACT: The most prevalent cause of cystic fibrosis (CF) is the
deletion of a phenylalanine residue at position 508 in CFTR (ΔF508-
CFTR) protein. The mutated protein fails to fold properly, is retained
in the endoplasmic reticulum via the action of molecular chaperones,
and is tagged for degradation. In this study, the differences in protein
expression levels in CF cell models were assessed using a systems
biology approach aided by the sensitivity of MudPIT proteomics.
Analysis of the differential proteome modulation without a priori
hypotheses has the potential to identify markers that have not yet been
documented. These may also serve as the basis for developing new
diagnostic and treatment modalities for CF. Several novel differentially
expressed proteins observed in our study are likely to play important
roles in the pathogenesis of CF and may serve as a useful resource for
the CF scientific community.
KEYWORDS: Cystic Fibrosis, cystic fibrosis transmembrane conductance regulator, CFTR, MudPIT, mass spectrometry, NSAF,
spectral count, label free, proteomics
■ INTRODUCTION
Cystic fibrosis (CF) is the most common lethal autosomal
recessive disease in the Caucasian population and is caused by
mutations in the cystic fibrosis transmembrane conductance
regulator (CFTR) gene. CFTR is a PKA-regulated chloride
channel localized at the apical surface of primary epithelia such
as those found in lung, pancreas, intestine, and kidney, where it
functions to regulate water and salt homeostasis. More than
1800 individual mutations have been reported in this
multidomain 1480-residue polytopic membrane glycoprotein
that give rise to a spectrum of differing disease severities and
symptoms (http://www.genet.sickkids.on.ca/cftr). The most
common mutation in humans (accounting for an estimated
75% of alleles and found in generally 90% of CF patients) is the
deletion of a phenylalanine at position 508 (ΔF508-CFTR) in
the CFTR protein. The F508 deletion prevents proper folding
of CFTR in the endoplasmic reticulum (ER) and impedes its
trafficking to its functional site at the cell surface. This mutant
version of CFTR is recognized as abnormal and remains
incompletely processed in the ER, where it is subsequently
degraded.1 As a consequence, cells expressing the mutant
protein are unable to transport chloride ions across the plasma
membrane in response to a rise in intracellular cAMP levels.
CF is referred to as a monogenic disease with a broad range
of lung disease severity even for patients who are homozygous
for the ΔF508 mutation.2 The non-CFTR genetic variants
(modifier genes) and/or environmental influences contribute
to the heterogeneity of pulmonary disease severity.2−4
However, in addition to the identification of modifier genes,
a complementary study employing a global proteomics
approach that looks at cells expressing wild-type and mutant
CFTR holds the potential for discovery of perturbed molecular
pathways underlying this complex disease process. The
rationale behind this assumption is that the F508 deletion
causes proteomic changes that otherwise would not be
predicted on the basis of known gene functions. Hence, the
interrogation at the level of the proteome and identification of
differentially expressed proteins can provide both a useful
overview of proteins involved in CF pathogenesis and the
opportunity to identify new therapeutic targets. Mass
spectrometry-based shotgun proteomics is an effective tool
for deciphering differences in biological systems at the
proteome level. The current generation of mass spectrometers
equipped with high-resolution and rapid-scanning mass
analyzers facilitates increased depth of proteome coverage,
allowing thousands of proteins to be routinely identified and
quantified from biological samples. Here, we used two-
dimensional liquid chromatography coupled to tandem mass
spectrometry (2D LC−MS/MS), also referred to as MudPIT
(multidimensional protein identification technology),5 in an
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LTQ Orbitrap Velos mass spectrometer to determine protein
expression changes in bronchial epithelial cell models6 of CF
disease, CFBE41o- (CFBE) and HBE41o- (HBE). We were
able to identify 349 differentially expressed proteins using a
spectral count label-free quantification approach. A subset of
deregulated proteins observed in our study belongs to key
biological processes that are of direct relevance to CF
pathogenesis, and the others are possibly involved in proteo-
stasis of CFTR processing.
■ MATERIALS AND METHODS
Materials
Tris(2-carboxyethyl) phosphine (TCEP), Tris, iodoacetamide,
sodium chloride, urea, and SDS were obtained from Sigma-
Aldrich (St. Louis, MO, USA). NP-40 was from Thermo Fisher
Scientific (Rockford, IL, USA). Sequencing grade trypsin was
from Promega (Madison, WI, USA).
Sample Preparation for Mass Spectrometry Analysis
Human bronchial epithelial cells stably expressing ΔF508-
CFTR (CFBE cells) or isogenic cells stably expressing wild-
type CFTR (HBE cells) were cultured as previously described.7
Cells were harvested by performing two washes in PBS and
incubating the plates with lysis buffer on ice for 20 min. The
lysis buffer (25 mM Tris, pH 7.6, 150 mM NaCl, 1% NP-40,
and 0.1% SDS) was supplemented with 1% protease inhibitor
mixture (Roche, Indianapolis, IN, USA). Lysis of cells was also
aided by sonication for 5 min in a water bath sonicator. Protein
lysates were clarified by centrifugation (13 500 rpm, 30 min at 4
°C). Protein concentration was determined by BCA protein
assay kit (Sigma, St. Louis, MO, USA).
A total of 200 μg of total cell lysate was precipitated by
adding a 4-fold volume of ice-cold acetone. This was incubated
at −20 °C for 2 h and then centrifuged at 10 000 rpm for 10
min at 4 °C. The pellet was air-dried. An initial reaction volume
of 100 μL was obtained by resuspending the pellet in Tris
buffer 50 mM, pH 8.0, containing an 8 M final concentration of
urea. The proteins were reduced with 5 mM TCEP for 20 min
and alkylated with 10 mM iodoacetamide for 15 min in the
dark. The reaction mixture was diluted to 2 M urea with 25
mM Tris, pH 8.0. Trypsin (Promega, Madison, WI, USA) was
added at an enzyme/substrate ratio of 1:50 (w/w). The
suspensions were then placed in a Thermomixer (Eppendorf,
Westbury, NY) and incubated overnight at 37 °C at 750 rpm.
The next day, the sample was acidified with formic acid to a
final concentration of 5% and spun at 14 000 rpm for 30 min.
Fifty micrograms of tryptic digest was aliquoted for MS
analysis.
Mass Spectrometry (MS) Analysis
MS analysis of the samples was performed using multidimen-
sional protein identification technology (MudPIT). Capillary
columns were prepared in-house from particle slurries in
methanol. An analytical RPLC column was generated by pulling
a 100 μm i.d./360 μm o.d. capillary (Polymicro Technologies,
Inc., Phoenix, AZ, USA) to 3 μm i.d. tip. The pulled column
was packed with reverse-phase particles (Aqua C18, 3 μm
diameter, 90 Å pores, Phenomenex, Torrance, CA, USA) until a
length of 15 cm was reached. A MudPIT trapping column was
prepared by creating a Kasil frit at one end of an undeactivated
250 μm i.d./360 μm o.d. capillary (Agilent Technologies, Inc.,
Santa Clara, CA, USA), which was then successively packed
with 2.5 cm strong cation-exchange particles (Partisphere SCX,
5 μm diameter, 100 Å pores, Phenomenex, Torrance, CA,
USA) and 2.5 cm reverse-phase particles (Aqua C18, 5 μm
diameter, 90 Å pores, Phenomenex, Torrance, CA, USA). The
trapping column was equilibrated using buffer A prior to sample
loading. After sample loading and prior to MS analysis, the
resin-bound peptides were desalted with buffer A by letting it
flow through the biphasic trap column. The trap and analytical
columns were assembled using a zero-dead-volume union
(Upchurch Scientific, Oak Harbor, WA, USA).
LC−MS/MS analysis was performed on LTQ Orbitrap Velos
(Thermo Scientific, San Jose, CA, USA) interfaced at the front
end with a quaternary HP 1100 series HPLC pump (Agilent
Technology, Santa Clara, CA, USA) using an in-house built
electrospray stage. Electrospray was performed directly from
the analytical column by applying the ESI voltage at a tee (150
μm i.d., Upchurch Scientific) directly downstream of a 1:1000
split flow used to reduce the flow rate to 250 nL/min through
the columns. A fully automated 10-step MudPIT run was
performed on each sample using a three-mobile-phase system
consisting of buffer A (5% acetonitrile (ACN); 0.1% formic
acid (FA) (Sigma-Aldrich, St. Louis, MO, USA)), buffer B
(80% ACN, 0.1% FA), and buffer C (500 mM ammonium
acetate, 5% ACN, 0.1% FA). The first step was a 60 min
reverse-phase run, whereas subsequent steps were of 120 min
duration. Each MudPIT run included steps with 10, 20, 30, 40,
50, 70, 80, and 100% buffer C run for 4 min at the beginning of
the gradient except for the last step, which included a salt bump
of 90% buffer C with 10% buffer B for 4 min.
As peptides were eluted from the microcapillary column, they
were electrosprayed directly into the mass spectrometer with
the application of a distal 2.4 kV spray voltage. Peptides were
analyzed using a top-20 data-dependent acquisition method in
which fragmentation spectra are acquired for the top 20 peptide
ions above a predetermined signal threshold. For each cycle,
survey full-scan MS spectra (m/z range 300−1600) were
acquired in the Orbitrap with the resolution set to a value of 60
000 at m/z 400, an automatic gain control (AGC) target of 1 ×
106 ions, and the maximal injection time of 250 ms. Each full
scan was followed by the selection of the most intense ions, up
to 20, for collision-induced dissociation (CID)-MS/MS analysis
in the ion trap. For MS/MS scans, the target value was 10 000
ions with an injection time of 25 ms. Once analyzed, the
selected peptide ions were dynamically excluded from further
analysis for 120 s to allow for the selection of lower-abundance
ions for subsequent fragmentation and detection using the
following settings: repeat count, 1; repeat duration, 30 ms; and
exclusion list size, 500. Charge state filtering, where ions with
singly or unassigned charge states were rejected from
fragmentation, was enabled. The minimum MS signal for
triggering MS/MS was set to 500, and an activation time of 10
ms was used. All tandem mass spectra were collected using a
normalized collision energy of 35% and an isolation window of
2 Th.
Data Analysis
Tandem mass spectra were extracted from the Xcalibur data
system format (.raw) into MS2 format using RawXtract1.9.9.2.
The MS/MS spectra were searched with the ProLuCID
algorithm against the human SwissProt database (downloaded
March 2014) that was concatenated to a decoy database in
which the sequence for each entry in the original database was
reversed. The search parameters include 10 ppm peptide
precursor mass tolerance and 0.6 Da for the fragment mass
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tolerance acquired in the ion trap; carbamidomethylation on
cysteine was defined as fixed modification in the search criteria.
The search space also included all fully and semitryptic peptide
candidates with a length of at least six amino acids. Maximum
number of internal miscleavages was kept unlimited, thereby
allowing all cleavage points to be considered. ProLuCID
outputs were assembled and filtered using the DTASelect2.08
program that groups related spectra by protein and removes
those that do not pass basic data-quality criteria. DTASelect2.0
combines XCorr and ΔCn measurements using a quadratic
discriminant function to compute a confidence score to achieve
a user-specified false discovery rate (1% for the current study).
We accepted only those proteins that were supported by two or
more lines of evidence.
For label-free quantification, normalized spectral abundance
factor (NSAF) values were calculated for proteins in each
sample to account for protein size and variability between
runs.9 Briefly, the NSAF for a protein k is the number of
spectral counts (SpC, the total number of MS/MS spectra)
identifying a protein, k, divided by the protein length (L),
divided by the sum of SpC/L for all N proteins in the
experimental design (eq 1).9
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A critical assumption that must be satisfied for use of
statistical approaches is that the data set being analyzed must
have a normal/Gaussian distribution.9 Following elucidation of
NSAF values, their natural logarithm (ln(NSAF)) was
calculated, and a density plot of the distribution of ln(NSAF)
values from replicates of each condition were generated to
show the normality of the distribution (Figure S1 in the
Supporting Information). After establishing that both CFBE
and HBE data sets fit a normal distribution, the data sets were
statistically compared to determine the significance of the
change between the two groups using Student’s t test (two-
tailed unpaired t test). To determine the relative abundance of
expressed proteins in CFBE cells relative to that in HBE, the
data set was first filtered to include only those proteins that
were detected in all three replicates for each condition and then
the ratio of the mean of the NSAF values from three biological
replicates of CFBE cells to the mean of NSAF values from three
biological replicates of HBE cells was computed. Proteins were
considered to exhibit significant expression changes with
log2NSAFCFBE/HBE ≥ 0.58 (p < 0.05) (overexpressed in CFBE
cells) and ≤ −0.58 (p < 0.05) (underexpressed in CFBE cells).
We discarded the proteins from further quantitative analyses
that were identified in both conditions but were found in less
than three replicates in each group because of poor
reproducibility. The NSAF value, t test, and ratio calculation
were performed using Microsoft Excel. The graphs were drawn
either in Excel or the R statistical package (http://www.r-
project.org/).
Preparation of Cell Lysates and Western Blotting
Cells grown in 6-well dishes were washed twice with ice cold
PBS and lysed in lysis buffer (50 mM Tris-HCl pH 7.4, 150
mM NaCl, 1% Triton X-100, and 2 mg/mL of complete
protease inhibitor cocktail) on ice for 30 min with gentle
rotation. Protein lysates were cleared by centrifugation at 14
000g for 15 min at 4 °C, and supernatants were collected for
further analysis. The protein concentration was assessed by
Bradford assay using the Coomassie protein assay reagent
(Thermo Fisher Scientific, Rockford, IL, USA). Aliquots of 15−
20 μg of total protein were separated by 8% or 4−20% SDS-
PAGE, transferred to nitrocellulose, and incubated with the
indicated primary antibodies overnight at 4 °C followed by IR-
dye labeled secondary antibodies in the dark at room
temperature for 1 h. Finally, the blots were scanned using the
LiCor Odyssey laser-based image detection method.
■ RESULTS AND DISCUSSION
In this study, we investigated the differential protein expression
between a cell line model of cystic fibrosis (i.e., bronchial
epithelial cells expressing ΔF508-CFTR (CFBE cells)) and
wild-type CFTR (HBE cells). The experimental approach used
in this study is outlined in Figure 1. The experiments were
performed in triplicate, that is, the procedure was repeated in
parallel for three culture plates of each condition. Each
biological replicate was processed in parallel to minimize the
effects of systematic errors. The proteins were isolated from
HBE and CFBE cells as described in the Materials and
Methods. The protein extracts were subsequently digested with
trypsin, and the resulting peptides were analyzed by LC−MS/
MS using the MudPIT method. The MudPIT technology is an
unbiased discovery-based method for rapid, yet nearly
comprehensive, proteome analysis where increasing levels of
salt are used for stepwise elution of peptides from the strong
cation-exchange (SCX) resin onto the reversed-phase resin
(vide supra).5 After each step elution from the cation-exchange
column, a reversed-phase gradient elutes the peptides into the
mass spectrometer according to their hydrophobicity, and MS/
MS are acquired automatically by data-dependent acquisition.
All mass spectrometry data collection preceded data analysis.
Three biological replicates were used for each cell type, and
from the analyses of replicates of the HBE group, 4307, 4474,
and 4415 proteins were identified, whereas 4326, 4372, and
4719 proteins were observed from the CFBE group (Table S1
in the Supporting Information). After consolidating proteins
from the replicate samples of each group, a total of 5296 and
5430 proteins were identified from the HBE and CFBE groups,
respectively. The bar graph shown in Figure S2 in the
Supporting Information shows a summary of the number of
proteins identified from the MS analyses of each replicate of the
two conditions and the cumulative identifications from three
replicates of each condition. The Venn diagram in Figure 2a,b
shows the comparison of proteins identified between replicate
Figure 1. Diagrammatic representation of the experimental approach
used for the comparative proteomic analysis of CF cell models, CFBE
and HBE.
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experiments within each group. The number of times a given
protein is detected reflects the reliability of the measurement.
As can be seen in the Venn diagram, an overlap of 68% (3586
out of 5296 total identified proteins in HBE cells) and 66%
(3566 out of 5430 total identified proteins in CFBE cells)
proteins was observed across all three replicates of HBE and
CFBE cells, respectively. In addition, a total of 3140 proteins
were found to be common to both HBE and CFBE groups
among all replicates (Figure S3 in the Supporting Information).
A spectral counting-based label-free approach was used for
quantitative profiling of CFBE versus HBE cells. Spectral count,
defined as the total number of MS/MS spectra acquired and
confidently assigned to a peptide, has proven to be a successful
label-free strategy for protein quantification.10,11 The raw
spectral counts were first transformed to yield normalized
spectral abundance factor (NSAF) values in order to adjust for
the variance in spectral count that occurs because of protein
length and the run-to-run variance in total spectral count
observed among experimental conditions.12 NSAF values allow
more accurate quantification of both the actual protein
abundances in a sample and the expression level changes
between multiple samples and experiments. The full lists of
proteins that were identified in each sample, three replicates of
HBE and three of CFBE, are provided in Table S1 in the
Supporting Information. To assess the data quality prior to
quantitative analysis, binary comparison of ln(NSAF) values of
common proteins identified among the replicate HBE and
CFBE samples was performed. The scatter plots shown in
Figure S4 in the Supporting Information reveal the distribution
of ln(NSAF) values along a diagonal line with very high
positive correlation, demonstrating high experimental reprodu-
cibility among biological replicates of each group. For relative
quantitative analysis, we used only proteins that were common
in all runs and identified in both CFBE and HBE cells, which
correspond to a total of 3140 proteins (Table S1 in the
Supporting Information). The relative abundance of proteins in
the CFBE versus HBE comparison was obtained by division of
the average NSAF values for each identified proteins in CFBE
cells with average NSAF values for the corresponding proteins
in HBE cells. The statistically significant differentially regulated
proteins in CFBE against HBE pairwise comparison were
subsequently selected on the basis of their p value (<0.05) and
the magnitude of change in relative abundance (NSAFCFBE/HBE)
of at least 1.5-fold. On the basis of this threshold, 349 proteins
were observed to be perturbed, with 218 proteins upregulated
in CFBE cells and 131 proteins downregulated compared to
HBE cells. A volcano plot of all 3140 quantified proteins from
the CFBE versus HBE data set displaying the relationship
between statistical significance (−log p value) and log2 ratio of
each protein is shown in Figure 3. The deregulated proteins
that are statistically significant (p < 0.05) are depicted in red
dots in the plot. Table S2 in the Supporting Information
provides the list of these proteins along with their UniProt IDs,
official gene symbol, NSAF values, p values, fold-change values
in logarithm to base 2, and the (raw) spectral counts identified
in each of the three biological replicates in each condition. The
stochastic nature of data acquisition by mass spectrometry
results in instances where proteins are identified in one
replicate but not in the other during the replicate sample
analysis from the same condition. The proteins that were
identified in less than three replicates in both HBE and CFBE
cells were discarded from quantitative analysis because of poor
reproducibility that would otherwise confound the expression
data. However, the proteins that were identified in all three
replicates in one or the other group were of particular interest,
so these uniquely identified proteins in all three replicates in
either HBE or the CFBE samples, labeled as “HBE specific” or
“CFBE specific”, are listed in Table S2 in the Supporting
Information. Because these proteins are observed only in the
HBE or CFBE sample, their ratio is not available to report.
The text mining tool Chilibot13 was used to find the
relationship between CFTR or CF and the statistically
significant, differentially expressed proteins in our study.
Chilibot searches the PubMed literature database (abstracts)
for specific relationships among proteins, genes, or keywords. It
automatically expands the supplied gene symbols to include its
synonyms and then queries PubMed and retrieves relevant
records. A subset of proteins detected as differentially expressed
in our study has been previously shown to play a role in CFTR
biogenesis. One example is protein-glutamine gamma-gluta-
myltransferase 2 (TGM2) that was upregulated by more than
11-fold in CFBE compared to HBE cells. A significant increase
of TGM2 protein and enzymatic activity in CF epithelium and
CFTR-defective cell lines have been demonstrated.14 TGM2 is
Figure 2. Venn diagrams showing the protein overlap in biological
replicates of each cell lines. (A) Venn diagram representing the
number of proteins observed for each of the three biological replicate
analysis of HBE sample as well as the protein overlap. (B) Venn
diagram showing similar observations as those in panel A; however,
the data was obtained from the analysis of replicates of CFBE cells.
Figure 3. Volcano plot of 3140 quantified proteins from the CFBE
versus HBE data set displaying the relationship between statistical
significance and fold change of each protein. The log2 fold change is
plotted on the x axis, and the −log p value is plotted on the y axis. The
red dots represent the 349 proteins that had statistically significant
differential expression, log2 fold change ≤ −0.58 or ≥ 0.58 (p < 0.05).
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a pleiotropic enzyme with a calcium-dependent transamidating
activity that results in cross-linking of proteins via ε(γ-glutamyl)
lysine bonds.15 TGM2 inhibition with cystamine has been
shown to rescue mutant CFTR and could become a therapeutic
target to control inflammation in CF and possibly in other
chronic inflammatory diseases.16 Figure 4a shows the proteins
that were observed to be differentially expressed in our data set
and that also have literature evidence for their functional
associations with CFTR or CF. Table S3 shows the role of
these proteins in CFTR biogenesis or CF pathogenesis and the
respective literature references. The list of identified candidates,
among which are some confirmations of previous findings,
increases the confidence in our data, and we believe that many
of the observed new markers could have potential relevance in
CF pathogenesis and/or CFTR proteostasis.
The clustering of 349 differentially regulated proteins that
were identified was performed according to their biological
processes on the basis of the gene ontology (GO) categories.
However, only 68% of the uploaded gene symbols were
mapped to the biological process GO terms by DAVID17
analysis. Hence, in addition to DAVID, the assessment of GO
categories was also performed using EnrichNet.18 CFTR, like
other membrane proteins, is synthesized and assembled in the
ER, where it is core-glycosylated.19 Once checked for correct
folding, this immature form of CFTR migrates to the Golgi
complex, where it undergoes further glycosylation. From the
Golgi apparatus, only the fully mature form is transported to
the plasma membrane, where it functions as a chloride channel.
Most of the immature wild-type (∼70%) and approximately
99% of misfolded ΔF508-CFTR are retained in the ER
compartment and are degraded via the cytosolic ubiquitin/
proteasome pathway.20−22 Because CF is a protein misfolding
disease, some of the enriched biological functions illustrated by
these functional annotation tools are of particular interest,
especially proteins involved in folding, response to unfolded
protein, endocytosis, proteolysis, and ubiquitin-mediated
degradation, among others. The differentially expressed
proteins that are representative of some of these key biological
functions, based on CF biology, are illustrated in Figure 4b.
Many molecular chaperones localized to the ER lumen and the
cytosol that have been shown to transiently associate with both
wild-type CFTR and ΔF508-CFTR were observed in our
analysis. Among the differentially expressed members of the
molecular chaperones and folding catalysts are heat shock
proteins (HSPs), such as HSPD1 (HSP60), HSPA6, HSPA1L,
DNAJC5, DNAJC11, TOR1A, and T-complex 1 subunit, TCP1
(aka CCT1). These proteins are known to interact selectively
and noncovalently with an unfolded protein, helping them to
achieve proper folding and preventing protein aggregation.
Peptidylprolyl isomerases are a class of folding catalysts that
Figure 4. (a) Bar graph displaying a subset of the statistically significant, differentially expressed proteins observed in our data set that have literature
evidence for their functional association with CFTR or cystic fibrosis. An online tool, Chilibot (http://www.chilibot.net/), was used to mine
PubMed for the relationships. See Table S3 in the Supporting Information for details. (b) Biological functions of a subset of the statistically
significant, differentially expressed proteins observed in our data set. The process annotation was obtained from online GO tools, DAVID (http://
david.abcc.ncifcrf.gov/), and Enrichnet (http://www.enrichnet.org/). FC, fold change (CFBE/HBE); square and triangular shapes represent down-
and upregulated proteins, respectively. The actual fold change value can be obtained from Table S2 (sheet 1) in the Supporting Information.
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accelerate potentially slow steps in the folding process. They
increase the rate of cis−trans isomerization of peptide bonds
involving proline residues; another class is protein disulfide
isomerases, which enhance the rate of formation and
reorganization of disulfide bonds.23 Peptidylprolyl isomerases,
such as PPIE and PPIF, were downregulated, whereas PPIL1
was upregulated in our data set. In a cell, a stringent quality
control mechanism exists that is capable of discriminating
normally folded proteins from abnormally folded proteins.24
Improperly folded proteins that could otherwise form
potentially toxic aggregates can be targeted for degradation
by the ubiquitin proteasome system. Degradation of a protein
by the ubiquitin system involves two successive steps,
conjugation of multiple moieties of ubiquitin and degradation
of the tagged protein by the proteolytic activity of the 26S
proteasome catalytic core. Several proteins with functional roles
in ubiquitin-mediated proteolysis were observed to have
differential expression, including ubiquitin-conjugating enzymes
(E2), UBE2L3; ubiquitin ligases (E3), CUL5 and STUB1;
deubiquitinating enzymes, UCHL1, UCHL3, and USP14; and
26S proteosomal subunits, PSMD14, PSMC5, and PSME3.
Calreticulin (CALR), upregulated in CFBE cells compared to
HBE in this study, has been shown to assist in CFTR assembly
and also to negatively regulate cell surface CFTR by enhancing
its endocytosis, leading to proteosomal degradation.25 The
endosome is a membrane-bounded organelle to which materials
ingested by endocytosis are delivered. The ΔF508-CFTR has
increased endocytic rate in the apical membrane, leading to
decreased CFTR-mediated chloride secretion.26 Endocytic
trafficking of CFTR from the membrane surface has implicated
several Rab proteins as being active players with distinct roles.
Interestingly, in our study, RAB5C was significantly upregulated
by more than 2-fold in CFBE cells. RAB5 has been shown to
play a role in initial internalization to early endosomes, and the
mutant protein can be rescued at the plasma membrane by
inhibition of Rab5-dependent endocytosis.27 RAB1A was also
mapped as being differentially regulated in our data set. In
addition, our comparative analysis also identified a cohort of
proteins with significant expression changes that are involved in
biological processes such as endocytosis, oxidation−reduction,
homeostasis, response to stress, apoptosis, and response to
wounding, among others (Figure S5).
The spectral count quantification results were further
validated by confirming the expression level of a subset of
differentially expressed proteins utilizing western blotting
(Figure S6). CFTR, like other membrane proteins, is
synthesized and assembled in the ER, where it is core-
glycosylated (also known as band B, ∼145 kDa). Once checked
for correct folding, this immature form of CFTR migrates to
the Golgi complex, where it undergoes full glycosylation (also
known as band C, ∼170 kDa). Approximately 99% of misfolded
ΔF508-CFTR protein is degraded before it reaches to the
plasma membrane. Only the fully mature form reaches the
surface membrane, where it functions as a chloride channel. As
seen in the western blot data, band C is the predominant band
in HBE cells, whereas only the immature form of CFTR (band
B) is observed in CFBE cells. Also observed were down-
regulation in the steady-state expression of BAG2 (cochaperone
of Hsp70/Hsc70) and elevation in the expression level of
calreticulin, thus corroborating the directionality of the fold
change observed with spectral counting results. Additional
proteins validated by western blot include calnexin, Hsp90,
Hsp70, Hsc70, inducible Hsp70 (Hsp70i), Hsp40, Rab5c,
Rab7, and Rab11.
To date, only a few studies have examined the proteomic
signatures of CF model systems.28 Using a hybrid approach
involving gene transfer and measurement of de novo
biosynthetic rates, Pollard et al. have identified 51 significantly
changing proteins in CF lung epithelial cells.29 Davezac et al.
have examined the role of misfolded CFTR on global protein
expression by comparing the effect of wild-type versus ΔF508-
CFTR overexpression in HeLa cells.30 Their study showed
elevation in the expression level of Keratin 8 and 18 (KRT8 and
KRT18) in the ΔF508-CFTR cells compared with that from
wild-type CFTR controls. A functional assay for CFTR
reported in their study revealed that reducing KRT18
expression resulted in increased trafficking of ΔF508-CFTR
to the plasma membrane. Interestingly, in our data set, we
observed 2-fold upregulation of KRT18 in ΔF508-CFTR cells
relative to that of wild type, thus corroborating the observation
of Davezac et al. A similar study involving comparison of wild-
type versus ΔF508-CFTR and ΔF508-CFTR(4RK), which
lacks the four arginine-framed tripeptide (RXR) motif of
CFTR, was performed in BHK cells.31 In addition, a
comparison of the proteome of BHK cell lines expressing
wild-type or ΔF508-CFTR, grown at 37 °C or low temperature
(28 °C), has been reported.32 Gharib et al. have studied the
patterns of protein expression in bronchoalveolar fluid (BALF)
samples from CF and control patients to understand the
mechanisms in the pathogenesis of CF lung disease.33 Many of
these expression-based studies have relied on an ability to
resolve proteins by two-dimensional (2D) gel electrophoresis,
which is limited because 2D gels are cumbersome to run, have a
poor dynamic range, and are biased toward abundant and
soluble proteins. The application of a non-gel, shotgun
approach with the MudPIT technique enabled us to delve
deeper into the whole-cell proteome to profile thousands of
proteins to identify significantly deregulated proteins. This
sensitivity is achieved mainly because MudPIT fractionates
peptides by 2D liquid chromatography that can be directly
interfaced with the ion source of a mass spectrometer.
Moreover, label-free measurement of protein expression is
simple and does not require prior labeling of proteins or
peptides with heavy isotopes. Although not as precise as other
methods of quantitative mass spectrometry, the semiquantita-
tive nature of spectral counting enabled us to create a rough
estimate of relative protein abundance, but in no way is an
indicator of absolute protein concentrations.
In summary, we have observed that the consequence of
ΔF508-CFTR expression in bronchial epithelial cells is quite
striking in terms of protein deregulation compared to that in
wild-type CFTR. Because the experiments were carried out in
human airway epithelial cells, the study has more general
relevance in the pathophysiology of CF. The quantitative data
provide a list of statistically significant proteins with a fold
change ≥ 1.5, and identification of these proteins in all three
biological replicates in each condition provides better
confidence in our results. The preliminary findings from this
comparison require further validation of the differences
observed as well as extension of the study to comparative
proteomics analysis of primary cells or tissue biopsies from CF
patients and healthy individuals. However, we need to keep in
mind that data obtained with cell lines may not be
representative of primary samples because cell culture
conditions do not always reflect the in vivo microenvironment.
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The challenge may also be exacerbated because of the
tremendous genetic heterogeneity between individual patients,
including modifier gene effects and environmental influences,
that affect the disease’s severity. Nevertheless, we believe that
the differentially regulated proteins identified in this study that
are presented both by effect size (i.e., fold change) and by
statistical significance (i.e., p value) may serve as a useful
resource for the CF community. The differentially regulated
proteins belong to wide range of biological functions and may
be involved in the underlying pathophysiology of a disease or as
part of the body’s response to the disease. Hence, monitoring
the proteins representative of these classes of biological
processes, although not specific for CF, are still of great
potential utility to track disease progression and therapeutic
intervention. The reported results could provide a basis for
targeted functional studies of specific proteins and might
potentially aid in developing a therapeutic strategy to correct
misfolding and/or augment mutant CFTR expression at the
plasma membrane. Once translocated to the membrane, the
latter is capable of forming cAMP gated chloride channels with
nearly normal conduction properties.
■ CONCLUSIONS
Deletion of a phenylalanine residue at position 508 in CFTR
protein is the most prevalent disease-causing mutation in CF
because it causes the protein to misfold, thereby negatively
affecting its intracellular trafficking. In this study, we present a
comprehensive comparative proteomic profiling of CFBE
versus HBE cells using a LC−MS/MS-based approach, with
the aim being to survey the molecular changes associated with
expression of ΔF508-CFTR in bronchial epithelial cells. We
incorporated analyses of three biological replicates for each of
the HBE and CFBE samples to overcome the data-dependent
variation in shotgun proteomic experiments and to obtain a
statistically significant protein data set with improved
quantification confidence. A total of 3140 proteins were
identified in all six samples, among which 349 proteins showed
statistically significant expression changes. Our data is
consistent with the notion that some of the differentially
regulated proteins are involved in protein folding and
degradation among many other biological processes, and
further investigation is needed to determine their relevant
roles in CF. CF is a complex disease, and all of the observed
changes may not be directly related to the presence of
misfolded CFTR protein. Nevertheless, this study provides a
scaffold upon which more directed and focused future studies
can be built.
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